In a study of adults previously infected with COVID-19, the Pfizer and Moderna COVID-19 vaccines offered additional protection against reinfection leading to hospitalization, the Centers for Disease Control and Prevention reported yesterday. Those who had completed a primary vaccine course and booster dose had the highest level of protection. A booster dose offered similar protection against hospitalization (60%-70%) after reinfection whether the delta or omicron variant predominated, while a first or second vaccine dose offered 50%-60% protection during the delta variant period and 35% during omicron.

Related News Articles

Headline
Adults age 65 and older are encouraged to receive an updated dosage of the COVID-19 vaccine, the Centers for Disease Control and Prevention announced April 25…
Headline
The Pfizer and Moderna COVID-19 vaccines can cause myocarditis, but do not appear to cause infertility, Guillain-Barré syndrome, Bell’s palsy, thrombosis with…
Headline
Centers for Disease Control and Prevention Director Mandy Cohen, M.D., Feb. 28 endorsed a recommendation by its Advisory Committee on Immunization Practices…
Headline
A CDC study  released Dec. 21 found low COVID-19 and flu vaccination coverage for most adults, and low RSV vaccination coverage for adults aged 60 and…
Headline
Fewer than one in four health care professionals working in acute care hospitals and nursing homes were up to date with COVID-19 vaccination during the 2022-23…
Headline
Children under age 12 should receive a 0.25 milliliter dose of the 2023-24 Moderna COVID-19 vaccine, not the full vial for that age group, the Food and Drug…